Immune checkpoint inhibitors (ICIs), such as programmed cell death protein 1 (PD-1) or programmed cell death ligand 1 (PD-L1), have become one of the most promising approaches in the treatment of advanced NSCLC patients whose tumor does not contain a driver mutation (3). This evidence concerns the gene CD274 and neoplasm.